Table 2.
Base-case cost–utility results for patients with mild-to-severe primary open angle glaucoma in rural setting
| Costs per person, US$ | QALYs per person | Incremental costs per person, US$ | Incremental QALYs per person | ICURs, US$ | |
| 5 years | |||||
| MMT | 3570 | 3.14 | – | – | – |
| TRAB | 7709 | 3.33 | 4139 | 0.19 | 21 462 |
| AGV implantation | 9017 | 3.34 | 5447 | 0.20 | 27 470 |
| GATT | 9848 | 3.37 | 6278 | 0.23 | 26 945 |
| ABiC | 10 471 | 3.38 | 6901 | 0.24 | 29 178 |
| 10 years | |||||
| MMT | 6458 | 5.65 | – | – | – |
| TRAB | 11 542 | 5.91 | 5084 | 0.26 | 19 675 |
| AGV implantation | 12 619 | 5.94 | 6161 | 0.29 | 21 151 |
| GATT | 12 613 | 5.97 | 6155 | 0.31 | 19 619 |
| ABiC | 13 598 | 6.05 | 7140 | 0.40 | 18 003 |
Costs are given in US dollars. ICURs were calculated against maximal medical treatment. The cost-effectiveness threshold was US$30 501 per QALY gained for rural setting and US$41 568 per QALY gained for urban setting.
ABiC, ab interno canaloplasty; AGV, Ahmed glaucoma valve; GATT, gonioscopy-assisted transluminal trabeculotomy; GDP, gross domestic product; ICUR, incremental cost–utility ratio; MMT, maximal medical treatment; QALY, quality-adjusted life-year; TRAB, trabeculectomy.